Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer

Stephen Dyar, Alvaro Moreno Aspitia

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

There is an ongoing need for development of new chemotherapeutic regimens for metastatic breast cancer [mBC], especially when tumors lack therapeutic targets such as the estrogen or progesterone receptor [ER/PR], or the human epidermal growth factor receptor-2 [HER2]. Capecitabine is an orally bioavailable fuoropyrimidine approved for monotherapy in mBC, and bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor which has shown to be active in mBC and tolerable in combination with other chemotherapeutics. The combination of these two agents has been explored in multiple phase II and III clinical studies, with improvements in progression-free survival and overall response rates noted as compared to capecitabine monotherapy. However, the use of bevacizumab in combination with capecitabine and other chemotherapy agents for mBC remains beset with controversy due to safety concerns, cost issues, and pending regulatory decisions.

Original languageEnglish (US)
JournalBreast Cancer: Basic and Clinical Research
Volume5
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Breast Neoplasms
Progesterone Receptors
Therapeutics
Estrogen Receptors
Vascular Endothelial Growth Factor A
Disease-Free Survival
Monoclonal Antibodies
Safety
Costs and Cost Analysis
Drug Therapy
Capecitabine
Bevacizumab
Neoplasms
human ERBB2 protein
Clinical Studies

Keywords

  • Bevacizumab
  • Capecitabine
  • Metastatic breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{1bf8442315b443558ab6eb4095b6320f,
title = "Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer",
abstract = "There is an ongoing need for development of new chemotherapeutic regimens for metastatic breast cancer [mBC], especially when tumors lack therapeutic targets such as the estrogen or progesterone receptor [ER/PR], or the human epidermal growth factor receptor-2 [HER2]. Capecitabine is an orally bioavailable fuoropyrimidine approved for monotherapy in mBC, and bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor which has shown to be active in mBC and tolerable in combination with other chemotherapeutics. The combination of these two agents has been explored in multiple phase II and III clinical studies, with improvements in progression-free survival and overall response rates noted as compared to capecitabine monotherapy. However, the use of bevacizumab in combination with capecitabine and other chemotherapy agents for mBC remains beset with controversy due to safety concerns, cost issues, and pending regulatory decisions.",
keywords = "Bevacizumab, Capecitabine, Metastatic breast cancer",
author = "Stephen Dyar and {Moreno Aspitia}, Alvaro",
year = "2011",
doi = "10.4137/BCBCR.S7379",
language = "English (US)",
volume = "5",
journal = "Breast Cancer: Basic and Clinical Research",
issn = "1178-2234",
publisher = "Libertas Academica Ltd.",
number = "1",

}

TY - JOUR

T1 - Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer

AU - Dyar, Stephen

AU - Moreno Aspitia, Alvaro

PY - 2011

Y1 - 2011

N2 - There is an ongoing need for development of new chemotherapeutic regimens for metastatic breast cancer [mBC], especially when tumors lack therapeutic targets such as the estrogen or progesterone receptor [ER/PR], or the human epidermal growth factor receptor-2 [HER2]. Capecitabine is an orally bioavailable fuoropyrimidine approved for monotherapy in mBC, and bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor which has shown to be active in mBC and tolerable in combination with other chemotherapeutics. The combination of these two agents has been explored in multiple phase II and III clinical studies, with improvements in progression-free survival and overall response rates noted as compared to capecitabine monotherapy. However, the use of bevacizumab in combination with capecitabine and other chemotherapy agents for mBC remains beset with controversy due to safety concerns, cost issues, and pending regulatory decisions.

AB - There is an ongoing need for development of new chemotherapeutic regimens for metastatic breast cancer [mBC], especially when tumors lack therapeutic targets such as the estrogen or progesterone receptor [ER/PR], or the human epidermal growth factor receptor-2 [HER2]. Capecitabine is an orally bioavailable fuoropyrimidine approved for monotherapy in mBC, and bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor which has shown to be active in mBC and tolerable in combination with other chemotherapeutics. The combination of these two agents has been explored in multiple phase II and III clinical studies, with improvements in progression-free survival and overall response rates noted as compared to capecitabine monotherapy. However, the use of bevacizumab in combination with capecitabine and other chemotherapy agents for mBC remains beset with controversy due to safety concerns, cost issues, and pending regulatory decisions.

KW - Bevacizumab

KW - Capecitabine

KW - Metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=83755174697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83755174697&partnerID=8YFLogxK

U2 - 10.4137/BCBCR.S7379

DO - 10.4137/BCBCR.S7379

M3 - Article

C2 - 22174585

AN - SCOPUS:83755174697

VL - 5

JO - Breast Cancer: Basic and Clinical Research

JF - Breast Cancer: Basic and Clinical Research

SN - 1178-2234

IS - 1

ER -